Pipeline

The Destiny Pharma Pipeline is based on the development and exploitation of the unique XF Drug Platform in a series of programmes for preventative and therapeutic antimicrobial pharmaceuticals. In addition the Company is progressing its proprietary PhotoBio medical device technology.

Clinical Development

XF-73, the Company's lead drug is in clinical development for the prevention of post-surgical Staphylococcal infection.
Europe:
XF-73 has completed three successful Phase I studies in the UK/EU. XF-73 is now preparing to progress into Phase II development in the EU.
U.S.:
XF-73 is preparing to progress into Phase I clinical development in the U.S.

Pre-clinical Development

XF-70, another drug from the XF Drug Platform is undergoing pre-clinical evaluation towards therapeutic antibacterial respiratory indications via the inhaled route.

Opportunities for the development of Destiny Pharma XF Drugs for a range of other antimicrobial applications exist including dermal, oral and systemic routes.

Bio-Defense

Recent collaborative research between Destiny Pharma and the Defence & Science Technology Laboratories (DSTL) have identified that portfolio compounds have significant activity against Bio-Defense microbial pathogens.

Data presented at the American Society of Microbiology Bio-Defense congress in Baltimore in 2010 exhibited Destiny Pharma compounds with activity against the following category II & III organisms:
Yersina (plague)
Burkholderia
Anthrax (vegetative)
Anthrax (spores)

Studies with US government agencies has also demonstrated activity of Destiny Pharma compounds against TB Destiny Pharma now is seeking collaborative relationships to further develop these Bio-Defense applications Contact the Company's Business Development department for further information on

PhotoBio

Destiny Pharma has developed a proprietary, 'integrated-surface' or 'matrix-based' molecular coating

PhotoBio is light activated to generate singlet oxygen to prevent, or to retard or to remove unwanted cellular attachment or growth on permanent/semi-permanent medical devices

A recent publication (Chambrier et al., 2010. Journal of Porphyrins and Phthalocyanines 14:81-88) has confirmed that PhotoBio leads the world in surface bound photodynamic coatings with impressive singlet oxygen quantum yields

Destiny Pharma has on-going industrial collaboration for the development of medicial devices

If you have need for the prevent of cell growth on any medical device please contact Destiny Pharma's Business Development department on .